ARA-290
most data
The Dose Guy’s verdictAug 29, 20264 sources
ARA-290 has something most peptides on this shelf do not: real human trial data showing it regrows small nerve fibers and quiets neuropathic pain. The catch is that every trial is small, the indication is narrow, and development stalled years ago. If you have small-fiber neuropathy or diabetic nerve pain and the standard options have failed, this is a real lead. For general healing or recovery, look at BPC-157 instead.
What it is
ARA-290 is an 11-amino-acid peptide pulled from the structure of erythropoietin, the hormone that tells your body to make red blood cells. But ARA-290 does not make red blood cells. It hits a different receptor, the innate repair receptor, a two-part receptor that shows up only where tissue is injured or inflamed. That selectivity is the whole point: it triggers a repair cascade without the blood-thickening risk that makes EPO itself dangerous to repurpose.
The niche is nerve repair. In sarcoidosis patients losing small nerve fibers and in diabetics whose corneal nerve density had already dropped below normal, ARA-290 measurably regrew those fibers and improved pain scores across multiple small trials. Nothing else on the healing shelf does that with human receipts behind it. If you want the standard soft-tissue and gut healing stack, start with BPC-157 and TB-500. ARA-290 only makes sense if your problem is nerve-related.
What the research shows
Small trials, narrow population, consistent signal. The human evidence is real but thin:
Realistic protocols
The diabetes and macular-edema trials both ran 4 mg subcutaneous, once daily, and the community copies that dose. ARA-290 clears from blood in minutes, but the biological effect is not about sustained blood levels. ARA-290 triggers an intracellular repair cascade through the innate repair receptor, and that cascade outlasts the peptide itself. So daily dosing works despite the fast clearance.
Run it for a defined stretch, not forever. The trials ran 28 days to 12 weeks. If you are targeting nerve pain or small-fiber symptoms, give it at least four weeks before judging, because nerve regrowth is slow tissue work. Do not expect a light-switch moment. What people describe is the burning or tingling dialing down gradually over weeks two and three, not disappearing on day four. If you are already on gabapentin or pregabalin, keep them running and use ARA-290 as the add-on, not the replacement, until you have your own data. There is no established maintenance protocol because no trial ran long enough to define one.
Side effects
Across all human trials, the safety signal has been quiet:
